Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9327)	3/23/1999 9:53:00 AM
From: dlc	Read Replies (1) \| Respond to of 17367

George, you correctly point out that there are two camps of opinion on the trial extension. Unfortunately neither side seems to have any facts to back up their position. This is very disturbing. You also point out with great insight that the standard of care seems to have improved in the UK and this may make it harder to judge the results of the trial. It does seem that the UK is making a much greater effort to diagnose and treat meningitis and related conditions. If their efforts bring the death rate down significantly, it could make Neuprex look innefective when it may in fact be a great drug for other indications. The FDA handling of MAGN should be a wake up call to everyone that the FDA doesn't really care about things like that. Without clear superiority, the FDA will likely reject it.